In a large cohort of R/R DLBCL (n = 135), TP53 mutations were identified in 51% of the patients, whereas only 21% of primary DLBCL (n = 1200) showed TP53 mutations, highlighting the importance of TP53 alterations in relapse initiation [34]. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.